Why do flat networks create so much regulatory risk in pharma breaches?

Why This Matters for Security Teams

Flat networks turn a single foothold into a regulatory event because they remove the practical boundaries that should keep development, corporate IT, and GxP systems from sharing the same blast radius. In pharma, that matters as much for auditability as for containment: if investigators cannot show which assets were isolated, monitored, or protected by least privilege, the estate can look uniformly exposed. NIST’s Cybersecurity Framework 2.0 and Zero Trust Architecture both point toward explicit trust boundaries, not implicit network trust.

That is why flatness becomes a compliance problem: segmentation failures can undermine evidence preservation, change control, and access accountability at the same time. NHIMG’s Ultimate Guide to NHIs — Regulatory and Audit Perspectives is useful here because many “network” weaknesses are actually identity governance failures, especially where service accounts, secrets, and privileged automation can move laterally without strong scope limits. In practice, many security teams discover this only after a vendor connection, misused service account, or compromised endpoint has already crossed from a low-risk subnet into regulated systems.

How It Works in Practice

In a regulated pharmaceutical environment, flat networks create risk by collapsing trust tiers that should be independently controlled. A workstation compromise can reach file shares, lab systems, manufacturing systems, or validation evidence repositories without traversing a controlled boundary. Once that happens, incident responders may have to treat a much larger set of systems as potentially impacted, which increases notification scope, investigation cost, and the chance that regulators question whether data integrity still holds.

The practical response is not “more monitoring only.” It is a layered containment model that combines network segmentation, identity segmentation, and control-plane visibility. NIST SP 800-53 Rev. 5 emphasizes access enforcement and system integrity controls, while Zero Trust Architecture supports verifying each request rather than trusting the network location. For pharma, that means:

• Separating GxP, corporate, lab, and third-party support zones with enforced policy boundaries.
• Restricting privileged access paths to named systems, named identities, and approved tasks.
• Limiting lateral movement with microsegmentation, one-way data flows where possible, and jump-host patterns.
• Inventorying NHIs, secrets, and automation accounts so service access is reviewed as tightly as human access.

NHIMG’s 52 NHI Breaches Analysis shows how often identity compromise becomes a wider incident, which is exactly why flat connectivity and over-scoped non-human access are dangerous together. When a compromised token can pivot into systems that should be isolated by function and regulatory status, the organization loses the ability to prove breach confinement. These controls tend to break down when legacy manufacturing networks, remote support tooling, and shared service accounts all depend on broad east-west connectivity because containment then conflicts with uptime and vendor access patterns.

Common Variations and Edge Cases

Tighter segmentation often increases operational overhead, requiring organisations to balance containment against validation effort, support complexity, and production uptime. That tradeoff is especially sharp in pharma because some environments include legacy instruments, vendor-managed appliances, or validated systems that were never designed for frequent network change. Current guidance suggests the answer is not to abandon segmentation, but to phase it carefully and document compensating controls where technical isolation is difficult.

There is no universal standard for this yet, but best practice is to classify zones by regulatory sensitivity and privilege, then apply the strictest controls to GxP, quality, and manufacturing execution paths. For AI-enabled or automation-heavy operations, that boundary should also include non-human identities and tool credentials, since those often become the shortest route around a network control. NHIMG’s Top 10 NHI Issues and Ultimate Guide to NHIs — Lifecycle Processes for Managing NHIs are useful reminders that access scope must be continuously retired, rotated, and reviewed, not only assigned.

Where regulations are interpreted conservatively, a flat or weakly segmented network can widen audit findings because the organisation cannot demonstrate proportional risk reduction. If AI systems are involved, the emerging governance view is that network design, identity scope, and model/tool access should be assessed together rather than as separate workstreams. That alignment is still evolving, and practitioners should treat it as a governance design choice rather than settled consensus.

Related resources from NHI Mgmt Group

• Why do vendor breaches create so much social engineering risk?
• Why do flat networks create more risk when attackers use AI?
• Why do dormant SaaS integrations create so much identity risk?
• Why do service accounts create so much hidden risk in SaaS stacks?